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1. Introduction 
Alzheimer’s disease is a debilitating dementia occurring in the elderly. Its pathological 
symptoms include forgetfulness and memory loss (Mattson, 2004). Disease imposes 
financial burden on family and society. Current line of treatment only provides 
symptomatic relief (Davis & Powchik 1995; Sugimoto et al., 1995). Drugs of purely curative 
or preventive type are still not marketed. Commonly used drugs are Acetylcholine esterase 
inhibitors (Sugimoto et al., 1995) which temporarily alleviate symptoms by raising levels of 
neurotransmitter Acetylcholine and thus improving cognitive behavior. These drugs are 
associated with a number of adverse side effects as well (Davis & Powchik, 1995). The aim of 
this chapter is to discuss strategies and hurdles in the design of preventive drugs. In the 
following section we briefly discuss causes behind onset and progression of disease as it is 
imperative to understand these issues. 
1.1 Generation of amyloid beta peptides and pathological condition of AD 
This disease is characterized by production of amyloid beta (Aǃ) plaques and intracellular 
neurofibrillary tangles in the brain  (cf. fig.1). Amyloid plaques are formed by aggregation of 
Aǃ peptide (Glenner & Wong, 1984) and neurofibrillary tangles are composed of hyper 
phosphorylated Tau protein (Alonso et al., 2001).  42 amino acid form of Aǃ has been 
identified as the predominant constituent of plaques (Yin et al., 2007). Therefore preventive 
and curative strategies deal with reduction in Aǃ 42 production. Aǃ peptides are generated 
by successive cleavages of amyloid precursor protein (APP) by ǃ and Ǆ secretase (Potter & 
Dressal, 2000) enzyme. Aǃ can also be cleaved by ǂ secretase enzyme. Cleavage by ǂ 
followed by Ǆ secretase leads to formation of another truncated form of Aǃ called P3. Aǃ 42 
is produced by cleavages taking place in Golgi (Hartman et al., 1997) apparatus. Cleavage of 
APP giving rise to different forms of Aǃ is shown in fig.2. Discovery and isolation of these 
enzymes has provided us the benefit of a target for preventive drug designing. ǃ secretase 
being the key enzyme involved has been assigned several popular names out of which ǃ 
amyloid precursor protein cleaving enzyme (BACE 2) is the most frequently used. BACE is a 
transmembrane protein with aspartyl protease family catalytic motif as in pepsin (Yan et al., 
2001). It is a homologous protein and interestingly not expressed in brain (Bennett et al., 
2000). It is still an important enzyme target as transgenic mice lacking BACE gene produce 
little or no Aǃ (Luo et al., 2003). 
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Damaged neuron in Alzheimer’s Disease 
Fig. 1. Shows a healthy neuron and presence of various enzymes. Encircled region shows 
formation of amyloid plaques and how they damage a healthy neuron 
 
 
Production of amyloid derived diffusible ligands 
Fig. 2. Shows formation of Aǃ 42 monomers, their subsequent oligomerization to form 
diffusible ligands and generation of Alzheimer’s symptoms 
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1.2 Past strategies for design of preventive drugs 
Researchers involved in developing drugs for AD have employed numerous strategies to 
combat this disease. Most of the techniques involved interfere in formation of Aǃ at some 
stage. 
1.2.1 Secretase inhibition 
Secretase enzyme is the most promising target. Inhibitors of ǃ secretase as well as Ǆ secretase 
have been synthesized. Both type of inhibitors stop formation of toxic Aǃ. Chemical 
structures for some of these potency values (Kazikowsky et al., 1996; Harel et al., 1996; 
Camps et al., 1999; Weihofen et al., 2003) are shown in fig.3. Despite numerous efforts these 
preventive drugs have not been able to reach our markets due to their poor 
pharmacodynamics and bioavailability problems. These problems have been largely 
associated with peptidic nature of BACE inhibitors and failure to design low molecular 
weight inhibitors. These compounds also show inhibitory effect on other signal transduction 
pathways and are hence undesirable from this point of view as well.  
1.2.2 Metal chelation 
Aǃ aggregation has been observed to be induced by several metal species including 
aluminum, iron, zinc and copper (Barnham et al., 2004). Therefore, apart from secretase 
inhibition anti aggregatory agents like metal chelators have been used which will remove 
metal ion  thus reducing aggregation of Aǃ peptide. Clioquinol, Deferriprone,  Curcumin etc 
are such drugs (Hanson et al., 2007) (c. f. fig. 4). Although metal chelators lead to behavioral 
improvements but they have not emerged as preventive alternatives. Energetic aspects 
related to inefficiency of these drugs have been studied in this chapter. 
1.2.3 NMDA receptor antagonism 
Persistent activation of CNS NMDA receptor has been hypothesized in AD patients. 
Therefore, NMDA receptor antagonists have also been tried out as possible AD drugs 
(Kemp & Mc Kernan 2002). Memantine (c.f. fig. 4) is such a recent FDA approved drug for 
AD. It protects neuro cells against excess glutamate by partially blocking NMDA receptor. 
1.2.4 MAO inhibitor 
Monoamine oxidase (MAO) inhibitors have shown neuroprotective activities; For example, 
selegiline, TVP1022, rasagiline (Sano et al., 1997; Ridderer et al., 2004; Yaudin & Buccafusco 
2005;  Huang et al., 1999) (cf. fig 5) have shown delayed progression of AD. MAO inhibition 
has also been considered as a strategy for controlling AD.  
1.2.5 Dual inhibition for synergistic effects  
In this strategy either two compounds are joined together to achieve better inhibition at a 
receptor (c. f. dual tacrine in fig. 5) or two compounds showing inhibitory activity at 
different receptors are joined to produce synergistic effects. Such examples include 
AChE/SERT dual inhibitors (Bolognesi  et al., 2005; Camps et al., 2005; Rosini et al., 2005; 
Kogen et al., 2002; Toda et al., 2002; Abe et al., 2003; Toda et al., 2003) (c. f. fig. 5). 
The aim of this chapter is to explain energetics involved in self aggregation of Aǃ. In silico 
design of a preventive drug based on understanding of underlying energetic aspects has 
been explored. A possible explanation for failures encountered in design of low molecular 
weight BACE 2 inhibitors has been provided. Design of low molecular weight preventive 
drugs is attempted. 
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Secretase inhibitors 
Fig. 3. Shows chemical structures of some ǃ and Ǆ-secretase inhibitors 
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Metal chelators 
Fig. 4. Shows chemical structures for some selected metal chelators 
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Dual inhibitors 
Fig. 5. Shows dual inhibitors which inhibit two targets (AChE/ SERT dual inhibitor) or 
show enhanced activity at single target (Huprine-tacrine heterodimer-enhanced activity at 
acetylcholinesterase enzyme) 
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2. Methodology 
Ab initio molecular orbital calculations in conjunction with intermolecular interaction 
calculations and docking studies have been performed to study energetics involved in self 
aggregation of Aǃ and drug……Aǃ interactions. Automated docking tools provided in 
Glide have been used for flexible ligand docking studies and generating poses for drug 
interacting with Aǃ or BACE. The whole procedure in brief may be summarized as follows. 
Aǃ solution structure was taken and minimized using Macromodel. Middle portion of Aǃ 
was taken for accurate ab initio calculations. Drugs and ions were docked in different poses 
(500 poses were generated) using GLIDE. Interaction energies were calculated ab initio for 
relevant poses using supermolecule calculations. All calculations have been carried out 
utilizing MAESTRO module of SCHRODINGER software (Maestro, 2010). 
3. Results and discussion 
Foremost Aǃ solution structure has been minimized keeping ionizable residues in ionized 
form. Middle piece of Aǃ (c.f. fig.6) was extracted to study Aǃ……ion interactions and 
possibility of self aggregation.  
 
 
Middle piece of Aǃ (16-23 residues) 
Fig. 6. Depicts optimized conformation of middle portion of amyloid peptide at 
physiological pH 
3.1 Energetics of self aggregation of Aβ 
It is not clear from literature whether self aggregation of Aǃ is metal induced or not. 
However, Zn2+ ions are known to play the dual role of neuroprotection as well as being 
neurotoxic. To understand neurotoxic role of Zn2+ ions we have studied affinity of Aǃ for 
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Int.en. =--499.70kCal/mol 
Affinity of Aǃ for Zn2+ ion 
Fig. 7. Depicts that amyloid beta peptide has great affinity for zinc ions. 
these ions and tendency for aggregation in presence of these ions. Fig. 7 indicates highly 
favored metal induced aggregation tendency. 
3.2 Role of an anti aggregatory compound 
Any compound may act as anti aggregatory in two possible ways – 
1. By removing toxic metal ions from brain 
2. By intercalating on to Aǃ and masking its portion actively involved in aggregation. 
Any attempt at designing anti aggregatory compound is bound to succeed if we first try 
to understand why metal chelator drugs used for removal of metal toxicity in the past are 
not so effective in present case. For a compound to be an efficient anti aggregation agent, 
it must be sufficiently competitive with metal ion for interaction at Aǃ. Curcumin and 
Chrysamine G are known to possess anti aggregation property as well as brain 
permeability. To understand their mode of action we have studied their metal chelation 
property and intercalative power. Fig. 8 depicts that both the drugs can remove metal 
toxicity. However, Curcumin will not be sufficiently competitive with Aǃ for metal ions. 
Chrysamine G can competitively inhibit metal induced aggregation by removing metal 
ion toxicity. Exploration of intercalative property of these compounds indicates that 
Curcumin cannot intercalate and Chrysamine G intercalates poorly. Therefore, it is 
understood that efficiency of preventive drugs depends on their ability to compete with 
Aǃ for metal ions which is extremely difficult as Aǃ has very high affinity for metal ions 
especially the middle piece. On the basis of this understanding we have tried to design a 
preventive compound that can compete with metal ions for Aǃ and can also intercalate to 
Aǃ. 
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                     Int.en. =-205.27 kCal/mol                         Int.en. =-712.46 kCal/mol 
 
 
                    Repulsive interaction                                              Int.en = -33.33Kcal/mol 
 
 
 
 
 
 
 
 
 
 
Metal chelation and intercalation of Aǃ by Curcumin and Chrysamine G 
Fig. 8. Shows possible modes of action for known anti aggregatory agents 
Curcumin 
Chrysamine G 
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3.3 Design of an intercalative preventive drug 
A peptidomimetic lead compound has been designed keeping in mind charge 
complementarity and conformational aspects of middle piece of Aǃ. A peptidomimetic 
compound has been designed to exploit peptide……peptide interactions for intercalation 
and to bring about specificity with the help of same. This compound contains peptide bonds 
in backbone here and there and substituents similar to amino acid residues toned according 
to needs to achieve good charge and conformational complementarity with Aǃ. Design of 
compound is based on visual examination of  length required for intercalation and anionic / 
cationic sites required for interaction to middle portion of Aǃ. 
Optimized conformation of lead compound and calculation of its metal removal efficiency 
are shown in fig. 9. Calculated metal interaction energies indicate that the compound will 
efficiently remove metal ions from brain. To study intercalative property of compound, 
flexible ligand docking studies have been performed. Drug……Aǃ interaction energies have 
been calculated in various poses and results of best poses are shown in fig. 10. Some of the 
important energetically filtered poses are shown in fig. 11. Calculated Aǃ……lead 
compound interaction energies clearly indicate that designed lead compound can compete 
with metal ions for Aǃ. At the same time it will also reduce concentration of metal ions from 
brain due to its metal ion removal efficiency. 
Intercalation is not through covalent linkage so that it does not bring about physical or 
chemical changes in the state of Aǃ peptide. The availability and concentration of metal ions in 
brain will decide on exact role of compound. This strategy of designing a curative drug is 
superior as compared to previous efforts where researchers have tried to break down 
aggregated Aǃ into smaller soluble Aǃ fragments as they only increase concentration of 
amyloid derived diffusible ligands (ADDLs). ADDLs have also been reported to cause certain 
problems due to their diffusible nature and high permeability. Our designed compound not 
only avoids aggregation of Aǃ 42 it also avoids  ADDLs from diffusing inside brain as they 
would increase molecular weight of ADDLs by intercalation. Pharmacokinetic aspects of lead 
compound can also be judged by considering compliance with rule of five.  
Designed compound has molecular weight slightly above 500, less than 5 hydrogen bond 
donor groups and less than 10 hydrogen bond acceptor groups. Thus it is expected to show 
sufficiently good pharmacokinetics. Being peptidomimetic it may show moderate 
bioavailability. Synthetic considerations and associated efficacy remain to be experimentally 
verified. This work emphasizes need for energetics based designing to attain desired efficacy. 
3.4 Design of a low molecular weight BACE inhibitor 
As mentioned in introduction BACE catalyzes cleavage of APP leading to formation of 
neurotoxic Aǃ peptide. Therefore, it is an obvious target for development of preventive drugs. 
Compounds inhibiting this enzyme are expected to block extracellular first cleavage of APP 
that subsequently leads to formation of Aǃ. BACE being an aspartyl protease catalyzes 
cleavage of APP assisted by two active site aspartyl residues which operate cooperatively with 
a net charge of -1. Most of the BACE inhibitors are transition state analogs derived from 
natural product pepstatin. Statine isostere has been derived from pepstatin and used to design 
transition state analogs for BACE that engage catalytic aspartics with a hydroxyl group. Some 
peptidic BACE inhibitors employing statine isostere are shown in fig. 12. These compounds 
have shown activity in enzymatic preparations but do not show appreciable activity in cellular 
assays. This attribute has been associated with the fact that they are peptides. The aim of this 
study is to understand mechanistic aspects of BACE  
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Metal chelation and intercalation of Aǃ by designed lead compound 
Fig. 9. Shows predicted modes of action of designed lead compound 
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Various poses for designed lead compound intercalating Aǃ 42 
Fig. 10. Shows automated flexible ligand docking results for designed lead compound 
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             Int.en. = -259.76 kCal/mol                                   Int.en. = -249.83 kCal/mol 
 
    
 
             Int.en. = -223.39 kCal/mol                                        Int.en. = -136.32 kCal/mol 
 
Interaction energies for designed lead compound masking middle portion of Aǃ 42 
Fig. 11. Shows preferred mode of action of designed lead compound  
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Peptidic inhibitors of BACE 2 
Fig. 12. Shows chemical structures of some peptidic inhibitors and their potencies 
inhibitors through molecular docking studies and intermolecular interaction calculations. 
Aim being to design reduced molecular weight compound with more ‘drug like features’. 
We first try to understand why low molecular weight peptide inhibitors have not been 
successful so far and why truncation of amino acid residues on either side of isostere leads 
to drastic loss in potency. 
3.4.1 Mechanistic aspects of small statine analog inhibitor of BACE 
Peptide inhibitors containing hydroxyethylene isostere or statine isostere show significant 
variation in potency from μM to nM range (c.f. fig. 12). Calculations and docking studies 
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have been performed on Peptide A to understand causes of loss in activity. Peptides possess 
conformational flexibility. A number of conformations (c.f. fig. 13) for Peptide A were 
generated using Ligprep module of SCHRODINGER. These conformations were 
energetically filtered for docking studies. Energetically filtered conformations were cyclic as 
small peptides (typically less than 10 amino acids) cannot attain stabilization through 
secondary structure that is ǃ-turn etc. Therefore, they possess greater tendency to cyclize 
and attain stabilization. To understand bioactive conformation and perform docking studies 
a model of BACE 2 active site has been prepared utilizing X- ray crystallography data for 
OM003 complexed in human BACE 2 (1M4H. pdb). This model covers 8Å environment 
around active site. All amino acid residues are taken in their normal occurring ionization 
states. For example, asp, glu, are negatively charged and lys, arg are positively charged. All 
possible protonation states of catalytic motif have been tried out in search of best 
mechanistic option. Best interaction energies obtained for peptide A conformation 1 and 2 
are shown in figs. 14 and 15. Flexible ligand, rigid protein dockings have been carried out. 
Asp 228 has been kept in ionized form in these calculations. Fig. 14 clearly indicates that the 
inhibitor cannot fit properly in the active site so as to interact efficiently with catalytic motif. 
In fact transition state isostere is oriented away from catalytic motif. The transition state 
isostere does not come in contact with catalytic motif. Interactions with asp 228 have been 
completely lost. There is no utilization of enhanced binding interactions that is, interacting 
residues in pockets of enzyme close to catalytic motif. Fig. 15 depicts docking results with 
conformation 2 of peptide A. Conformation 2 is still worse in terms of interactions with 
active site residues. Inhibitor can fit in active site only at distances 6 and 8Å from catalytic 
motif  due to its conformation. At these distances very little interaction with catalytic motif 
can be achieved. Interaction with asp 228 becomes impossible due to highly spatially 
constrained active site of BACE 2 and the conformational aspects of inhibitor. 
These docking results when compared with X-ray crystallography data for OM003 
complexed in BACE 2 reveal that low molecular weight peptide inhibitors show 
conformationally controlled mechanistic aspects leading to decrease in their potency. Cyclic 
type conformations impart stability to small peptides but render them unsuitable for spatial 
requirements of BACE 2 active site leading to drastic reduction in activity. This 
understanding led us to design conformationally stable low molecular weight lead 
compound.  
3.5 Design of low molecular weight BACE inhibitor 
Designing has been strategically and systematically pursued. Peptide backbone has been 
replaced with peptidomimetic backbone to control conformational problems. Residues 
similar to natural substrate have been retained for specificity. Drug has been designed to 
be a competitive inhibitor as opposed to transition state analog.  Transition state isostere 
containing hydroxyl group to engage catalytic aspartic dyad has been replaced with a 
positive site to electrostatically interact with ionized asp 228 of active site for binding 
interactions (c.f. fig. 16). Conformational aspect is not an issue in this case. Designed 
compound was subjected to in silico testing that is, docking studies were performed to 
judge its activity. Best results of docking studies are shown in fig. 16. Designed lead 
compound can fit in active site and interact with catalytic motif. Fig. 16 shows that 
interaction energy predicted is not particularly attractive but indicates that lead 
compound may bind with retention of conformation leading to perhaps enhanced 
bioavailability and good potency. 
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                                                             Conformation 1                     Conformation 2 
Energetically filtered conformations of Statine isostere containing Peptide A 
Fig. 13. Shows bioactive conformations of peptide A 
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Peptide A (conformation 1) interacting with BACE 2 catalytic motif 
Fig. 14. Shows mode of action of a small peptidic inhibitor of BACE 2 
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Peptide A (conformation 2) interacting with BACE 2 catalytic motif 
Fig. 15. Shows mode of action of a small peptidic inhibitor of BACE 2 
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Int. en. = -9.95 kCal/mol 
 
 
Designed competitive inhibitor interacting with BACE 2 catalytic motif 
Fig. 16. Shows predicted mode of action of a designed compound as competitive inhibitor of 
BACE 2 
4. Conclusions 
This chapter describes ab initio Hartree Fock molecular orbital calculations combined with 
docking tools and intermolecular interaction calculations on amyloid beta peptide. Energetics 
involved in metal ion induced self aggregation of amyloid beta peptide has been studied. Study 
indicates that metal induced self assemblage of Aǃ is highly favored. Any compound can act as 
an anti aggregatory agent if it can compete with Aǃ for metal ions. To be competitive it must 
have an interaction energy of ~500 kCal/mol with metal ions like Zn2+ ion. Intercalative and 
metal detoxification properties are desired in prospective preventive drug for AD. A 
peptidomimetic lead compound with these properties has been designed and tested in silico. 
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Mechanistic aspects of peptide inhibitors of BACE 2 have been studied in detail. Mode of 
action of peptide transition state analog drugs has been highlighted. Conformationally 
controlled mechanistic aspects of low molecular weight peptide inhibitors have been 
discussed. Low molecular weight peptide inhibitors tend to possess cyclic type 
conformation which is not suitable for interactions with catalytic motif. Large peptide 
inhibitors on the other hand show bioavailability problems due to their poor 
pharmacokinetics and membrane permeability problems. An attempt has been made at 
designing conformationally stable, reduced molecular weight lead compound that follows 
Lipinski’s rule and is expected to cross cell membranes. Designed compound is competitive 
inhibitor as opposed to transition state analog. Designed lead compound is reduced 
molecular weight and is expected to retain specificity as it utilizes same sequence of amino 
acid residues as in natural substrate APP. Designed compound is expected to overcome 
conformational complications, bioavailability however remains to be asserted by 
experimental studies. 
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